<DOC>
	<DOCNO>NCT01213147</DOCNO>
	<brief_summary>Despite progression assist reproductive technology ( ART ) , prefer protocol poor responder still controversial . The management poor responder consist 10 % ART cycle . The response control ovarian hyperstimulation ( COH ) low regard estradiol level , number obtain oocyte , fertilization , implantation pregnancy rate patient low ovarian reserve . Furthermore , bad quality embryos observe woman normoresponders increase cancellation rate dos gonadotropin administration remarkable result poor responder . Several criterion introduce poor responder , main defect management lack specific definition .Several strategy available improve ART cycle outcome poor responder . These modality include use : high FSH dose , stop GnRH-agonist protocol , addition growth hormone , transdermal testosterone , aromatase inhibitor , GnRH-antagonist recombinant FSH ( r-FSH ) ; improvement pregnancy rate quite low . The common use protocol ovarian stimulation microdose GnRH-agonist flare poor responder .Some investigator conclude use GnRH-agonist `` even low dos , lead prolonged stimulation increase cost without improve IVF outcome . Furthermore method increase LH , progesterone androgen serum follicular phase , cause deleterious effect follicular growth oocyte quality . Clomiphene citrate co-treatment gonadotropin antagonist one recommend protocol poor responder . Clomiphene citrate increase endogenous FSH versus agonist microdose protocol . Decreasing dos use gonadotropin duration stimulation beneficial effect COH cycle . The aim study compare CC/gonadotropin/antagonist GnRH agonist flare protocols IVF outcome poor responder .</brief_summary>
	<brief_title>Mild Stimulation Protocol Versus Microdose Gonadotropin-releasing Hormone Agonist Flare Protocol Poor Responders</brief_title>
	<detailed_description>Despite progression assist reproductive technology ( ART ) , prefer protocol poor responder still controversial . The management poor responder consist 10 % ART cycle . The response control ovarian hyperstimulation ( COH ) low regard estradiol ( E₂ ) level , number obtain oocyte , fertilization , implantation pregnancy rate patient low ovarian reserve . Furthermore , bad quality embryos observe woman normoresponders increase cancellation rate dos gonadotropin administration remarkable result poor responder Several criterion introduce poor responder , main defect management lack specific definition .Several strategy available improve ART cycle outcome poor responder . These modality include use : high FSH dose , stop GnRH-agonist protocol , addition growth hormone , transdermal testosterone , aromatase inhibitor , GnRH-antagonist recombinant FSH ( r-FSH ) ; improvement pregnancy rate quite low . The common use protocol ovarian stimulation microdose GnRH-agonist flare poor responder .Some investigator conclude use GnRH-agonist `` even low dose `` lead prolonged stimulation increase cost without improve IVF outcome . Furthermore method increase LH , progesterone androgen serum follicular phase , cause deleterious effect follicular growth oocyte quality . Clomiphene citrate co-treatment gonadotropin antagonist one recommend protocol poor responder . Clomiphene citrate increase endogenous FSH versus agonist microdose protocol . Decreasing dos use gonadotropin duration stimulation beneficial effect COH cycle . The aim study compare CC/gonadotropin/antagonist GnRH agonist flare protocols IVF outcome poor responder . Materials Methods Study design This study prospective randomize controlled trial include 159 poor responder patient candidate IVF . Women ≥38 year old one previous fail IVF cycle three few oocyte retrieve and/or serum E2 level day hCG administration ≤500 pg/ml enrol study . Patients BMI &gt; 30 , endocrine metabolic disorder , history ovarian surgery , sever endometriosis sever male factor ( azospermia ) exclude study . Patients divide two group , 79 woman group I receive CC/gonadotropin/antagonist ( mild protocol ) 80 woman group II receive microdose GnRH-agonist flare ( microdose protocol ) . A method computer-generated randomization use . Treatment Protocols All woman receive oral contraceptive 21 day start first day previous cycle . In group I , stimulation perform administration clomiphene citrate ( Iran hormone , Tehran , Iran ) 100 mg day 3 withdrawal bleed day 7 cycle gonadotropin stimulation 225-300 IU daily , recombinant FSH ( r-FSH ) SC hMG IM , start day 5 cycle . In group II ovarian stimulation initiate GnRH-agonist , buserelin ( Suprefact , Aventis Pharma , Frankfurt , Germany ) 50 µg SC twice day cycle day 2 withdrawal bleeding . After two day , 225-300 IU/day recombinant FSH ( r-FSH ) SC hMG IM administer . Ovarian response monitor serial ultrasound examination evaluation serum E₂ level , dos gonadotropin adjust required group . In group I , least one follicle ≥ 14 mm mean diameter observe , 0.25 mg GnRH antagonist ( ganirelix , Organon , netherlands ) SC daily start continued hCG injection . Urinary Human chorionic gonadotropin 10000 IU administer intramuscular least two follicle reach mean diameter 18 mm group . Also , endometrial thickness serum E₂ level measure day hCG injection .Oocyte retrieval perform 34-36 hour hCG injection conventional IVF intracytoplasmic sperm injection ( ICSI ) do appropriately . All embryo score number , size , shape , symmetry cytoplasmic appearance blastomers , presence anucleate cytoplasmic fragmentation . Based number quality available embryos patient 's age , one five embryo transfer day 2 3 oocyte retrieval ultrasound guidance CCD embryo transfer catheter ( Laboratory C.C.D. , Paris , France ) . Luteal support progesterone 100 mg daily IM start day oocyte retrieval continue documentation fetal heart activity ultrasound . Cycle cancellation define three group : [ 1 ] poor ovarian response : few two grow follicle transvaginal ultrasound , E₂ level &lt; 200 pg/ml day 7 stimulation ; [ 2 ] fail oocyte retrieval : obtain oocyte day ovarian puncture ; [ 3 ] fail fertilization : fertilize oocyte IVF/ICSI .</detailed_description>
	<mesh_term>Clomiphene</mesh_term>
	<mesh_term>Enclomiphene</mesh_term>
	<mesh_term>Zuclomiphene</mesh_term>
	<mesh_term>Buserelin</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Women ≥38 year old woman one previous fail IVF cycle three few oocyte retrieve and/or serum E2 level day hCG administration ≤500 pg/ml enrol study BMI &gt; 30 endocrine disorder metabolic disorder history ovarian surgery sever endometriosis sever male factor ( azospermia )</criteria>
	<gender>Female</gender>
	<minimum_age>38 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Pregnancy</keyword>
	<keyword>Clomiphene Citrate</keyword>
	<keyword>Fertilization</keyword>
	<keyword>Buserelin</keyword>
</DOC>